Axis Direct
Considering overall stellar performance we have incresed earnings for FY22E & FY23E and increased target price to INR 1,670 with Buy recommendations.
Solara Active Pharma Sciences Ltd. has lost -31.56% in the last 6 Months
More from Solara Active Pharma Sciences Ltd.
Recommended